^
    Back
    Association details:
    Biomarker:FGFR2 mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASCO-GU 2023
    Title:

    Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).

    Published date:
    02/13/2023
    Excerpt:
    In this multisite retrospective study, the presence of FGFR2/3 alterations was associated with lower ORR and shorter PFS in pts with aUC treated with ICI.
    DOI:
    10.1200/JCO.2023.41.6_suppl.478